Abstracts tagged "Cohort Study"

Abstract Number: 0484 • ACR Convergence 2023
Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study
Lihi Eder¹, Vinod Chandran², Cheryl Rosen³, Richard J. Cook⁴ and Dafna Gladman⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Dermatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Simple and accessible biomarkers that predict the development of psoriatic arthritis (PsA) among psoriasis patients are critically needed to improve early detection of high-risk…
Abstract Number: 0845 • ACR Convergence 2023
The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy marques¹, Sofia Ramiro², Miranda Van Lunteren³, Rosalinde Stal³, Robert BM Landewé⁴, Marleen van de Sande⁵, Karen Minde Fagerli⁶, Inger Jorid Berg⁶, Maikel van oosterhout⁷, Sofia Exarchou⁸, Roberta Ramonda⁹, Désirée van der Heijde² and Floris Van Gaalen³, ¹Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁵Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ⁶Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands, ⁸Lund University, Åkarp, Sweden, ⁹University of Padova, Department of Rheumatology, Padova, Italy
Background/Purpose: We have shown in the SPACE cohort that a diagnosis of early axial Spondyloarthritis (axSpA) can be reliably made in patients with chronic back…
Abstract Number: 1462 • ACR Convergence 2023
Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
Sara garcia Perez¹, Jose-Maria Pego-Reigosa², Irene Altabás González¹, Norman Jiménez³, Victor Del campo Perez⁴, JULIA MARTINEZ BARRIO⁵, Maria Galindo-Izquierdo⁶, Jaime Calvo- Alén⁷, Esther Uriarte Isacelaya⁸, Eva Tomero Muriel⁹, Mercedes Freire González¹⁰, Victor Martinez-Taboada¹¹, Paloma Vela¹², Antonio Fernandez-Nebro¹³, Alejandro Olivé-Marqués¹⁴, Javier Narvaez¹⁵, Raúl Menor-Almagro¹⁶, Gregorio Santos Soler¹⁷, José Ángel Hernández Beriain¹⁸, Javier Manero ruiz¹⁹, Elena Aurrecoechea Aguinaga²⁰, Oihane Ibarguengoitia-Barrena²¹, Carlos Montilla-Morales²², Gema Bonilla²³, Vicente Torrente-Segarra²⁴, Ana Paula Cacheda²⁵, Maria J. García-Villanueva²⁶, Clara Moriano Morales²⁷, Concepción Fito Manteca²⁸, Cristina Bohórquez²⁹, Nuria Lozano Rivas³⁰ and Iñigo Rúa-Figueroa³¹, ¹Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁴Department of Epidemiology, University Hospital of Vigo, IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ⁵Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁶Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ⁹Rheumatology, Hospital La Princesa, Madrid, Spain, ¹⁰Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹¹Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹²Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹³Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁴Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ¹⁷Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ¹⁸Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, ²⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²²Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁴Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²⁵Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ²⁶Hospital Ramón y Cajal, Madrid, Spain, ²⁷Rheumatology, Hospital Universitario de León, León, Spain, ²⁸Department of Rheumatology, University Hospital of Navarra, Pamplona, Spain, ²⁹Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, ³⁰Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…
Abstract Number: 2299 • ACR Convergence 2023
Medication-related Hospitalizations in Systemic Lupus Erythematosus
Michele Stanciu¹, Evelyne Vinet², Emily Gibson McDonald³, Gregory Clark³, Christian Pineau², Fares Kalache⁴, Louis-Pierre Grenier⁵, Sasha Bernatsky⁶ and Arielle Mendel³, ¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Carignan, AB, Canada, ⁵Montreal General Hospital, Montréal, QC, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Adverse drug events (ADEs; harm from use of a drug) cause a significant burden to the healthcare system, with an estimated 5% of hospitalizations…
Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Emily Zhang¹, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan¹, Mindy Lo¹, Olha Halyabar², Melissa Hazen¹, Ezra Cohen³, Lauren Henderson¹, Siobhan Case⁴, Margaret Chang¹, Camille Frank¹, Ankana Daga¹, Jonathan Hausmann⁵, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma¹, Mia Chandler⁶, Fatma Dedeoglu¹, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁷, Mary Beth Son¹ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, ⁶Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
Abstract Number: 0301 • ACR Convergence 2022
Effectiveness and Safety of Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Third Interim Analysis of a German Non-Interventional, Prospective, Multicenter Study (ESCALATE-RA)
Klaus Krüger¹, Ulrich Prothmann², Thilo Klopsch³, Olaf Behmer⁴, Min-Jean Hsieh⁴, Jürgen Jobst⁴, Pascal Klaus⁴ and Thomas Meng⁴, ¹Praxiszentrum St. Bonifatius, Rheumatology, München, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Germany, ³Rheumatological Practice, Neubrandenburg, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. ESCALATE-RA is the first prospective, non-interventional study with tofacitinib in Germany.Methods:…
Abstract Number: 0934 • ACR Convergence 2022
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jinhyun Kim⁴, Eun Bong Lee¹ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ³Ajou University School of Medicine, Suwon, Republic of Korea, ⁴Chungnam National University Hospital, Jung-gu, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
Abstract Number: 1320 • ACR Convergence 2022
Performance of FRAX® Brazil and NOGG Methodology with and Without Bone Mineral Density upon Predicting Fractures on a Community-Dwelling Elderly Population with High Incidence of Osteoporotic Fractures: The São Paulo Ageing and Health (SPAH) Study
Thiago Q Freitas¹, Leonardo F G Olalla¹, Liliam Takayama¹, Valeria Caparbo², camille figueiredo², Luana Machado³, Diogo Domiciano⁴ and Rosa Pereira², ¹University of São Paulo, São Paulo, Brazil, ²Bone Metabolism Laboratory, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: SPAH is a prospective cohort of ≥65-year-old community-dwelling elderly with high fracture risk (40.3/1,000 person-years in women and 30.6/1,000 in men for vertebral fractures…
Abstract Number: 1780 • ACR Convergence 2022
Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases
Paola Ghanem¹, Joseph C. Murray¹, Christopher Mecoli², Ami Shah³, Benjamin Levy¹, Kristen A. Marrone¹, David Ettinger¹, Valsamo Anagnostou¹, Vincent K. Lam¹, Julie R. Brahmer¹ and Laura C. Cappelli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Lung cancer remains the leading cause of cancer-related death. Concomitant autoimmune diseases (AD) can add morbidity and complicate treatment decisions. We evaluated the tumor…
Abstract Number: 2025 • ACR Convergence 2022
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
Brandon Law¹, Margaret Beach², Eileen Pelayo², Ilias Alevizos², Zohreh Khavandgar², Blake Warner² and Alan Baer¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
Abstract Number: 1014 • ACR Convergence 2022
Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?
Manouk de Hooge¹, Alla Alexeevna Ishchenko², Serge Steinfeld³, Adrien NZEUSSEU TOUKAP⁴, Dirk Elewaut⁵, Rik Lories⁶, Filip Van den bosch⁷ and Kurt de Vlam⁸, ¹Ghent University Hospital, Luxembourg, Luxembourg, ²University Hospitals Leuven, Sint-Stevens-Woluwe, Belgium, ³Clinique Saint-Jean, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁵Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁸University Hospitals Leuven, Leuven, Belgium
Background/Purpose: There is an ongoing debate on axial involvement in psoriatic arthritis (PsA). This study, using clinical and radiographical definitions of axial involvement, investigated the…
Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 1811 • ACR Convergence 2022
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Emily Fan¹ and Megan Krause², ¹University of Kansas School of Medicine, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Identifying patients with gout who would benefit from urate lowering therapies (ULT) is of utmost importance to help limit both pain and functional pain.…
Abstract Number: 2049 • ACR Convergence 2022
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Phoung Phoung Diep¹, Karoline Lerang², Birgir Gudbransson¹, Helena Andersson¹, Øyvind Midtvedt¹, Torhild Garen¹, Michael Durheim¹, Trond Mogens Aaløkken¹, Øyvind Palm¹ and Øyvind Molberg², ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].